Method for the preparation of antibody-fragment conjugates

Claim 3

The method according to claim 1, in which the thiol protease is bromelain, papain, chymopapain or ficin.

Claim 4

The method according to claim 1, in which the thiol protease is activated by reacting it with cysteine or a sulfhydryl reducing agent selected from the group consisting of dithiothreitol, mercaptoethanol and mercaptoethylamine.

Claim 5

The method according to claim 1, in which the antibody-compound conjugate is formed by a method, comprising: (a) reacting an antibody with an oxidizing agent to form an aldehyde group in a carbohydrate moiety of the antibody located outside the antigen binding region of the antibody; and (b) reacting the aldehyde group of the resultant oxidized carbohydrate moiety of the antibody with an amine group of a compound selected from the group consisting of primary amine, secondary amine, hydrazine, hydrazide, hydroxylamine, phenylhydrazine, semicarbazide and thiosemicarbazide groups, to form a soluble antibody-compound conjugate being characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the antibody compound conjugate is suitable for in vivo administration.

Claim 6

The method according to claim 4, in which the oxidizing agent is an enzyme.

Claim 7

The method according to claim 4, in which the oxidizing agent is an oxygen acid.

Claim 10

The method according to claim 7, in which the thiol protease is bromelain, papain, chymopapain or ficin.

Claim 11

The method according to claim 7, in which the antibody-linker intermediate is formed by a method, comprising: (a) reacting an antibody with an oxidizing agent to form an aldehyde group in a carbohydrate moiety of the antibody located outside the antigen binding region of the antibody; and (b) reacting the aldehyde group of the resultant oxidized carbohydrate moiety of the antibody with an amine group of a linker selected from the group consisting of primary amine, secondary amine, hydrazine, hydrazide, hydroxylamine, phenylhydrazine, semicarbazide and thiosemicarbaozide groups, to form a soluble antibody-linker intermediate being characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the antibody-linker intermediate is suitable for in vivo administration.

Claim 12

The method according to claim 9, in which the oxidizing agent is an enzyme.

Claim 13

The method according to claim 9, in which the oxidizing agent is an oxygen acid.

Claim 16

The method according to claim 12, in which the thiol protease is bromelain, papain, chymopapain or ficin.

Claim 17

The method according to claim 12, in which the antibody-linker-compound conjugate is formed by a method, comprising: covalently or coordinately attaching a linker portion of an antibody-linker intermediate which comprises a linker covalently attached to an oxidized carbohydrate moiety of an antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody, to a compound to form a soluble antibody-linker-compound conjugate being characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration.

Claim 18

The method according to claim 12, in which the antibody-linker-compound conjugate is formed by a method, comprising: (a) reacting an antibody with an oxidizing agent to form an aldehyde group in a carbohydrate moiety of the antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody; (b) reacting the aldehyde group of the resultant oxidized carbohydrate moiety of the antibody with an amine group of a linker containing an amine group selected from the group consisting of primary amine, secondary amine, hydrazine, hydrazide, hydroxylamine, phenylhydrazine, semicarbazide and thiosemicarbazide groups, to form an antibody-linker intermediate; and (c) covalently or coordinately attaching a compound to the linker portion of the antibody-linker intermediate to form an antibody-linker-compound conjugate being characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration.

Claim 19

The method according to claim 12, in which the antibody-linker-compound conjugate is formed by a method, comprising: covalently attaching an amine group of a linker moiety of a linker-compound intermediate containing a reactive amine group selected from the group consisting of primary amine, secondary amine, hydrazine, hydrazide, hydroxylamine, phenylhydrazine, semicarbazide and thiosemicarbazide group to an oxidized carbohydrate moiety of an antibody to form an antibody-linker-compound being characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration.

Claim 20

The method according to claim 12, in which the antibody-linker compound conjugate is formed by a method, comprising: (a) reacting an antibody with an oxidizing agent to form an aldehyde group in a carbohydrate moiety of the antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody; (b) reacting the aldehyde groups of the resultant oxidized carbohydrate moiety of the antibody with an amine group of a linker-compound intermediate containing an amine group selected from the group consisting of primary amine, secondary amine, hydrazine, hydrazide, hydroxylamine, phenylhydrazine, semicarbazide and thiosemicarbazide to form an antibody-linker-compound conjugate, being characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration.

Claim 21

The method according to claim 1, 7 or 12, in which the antibody is a monoclonal antibody.

Claim 22

The method according to claim 7 or 12, in which the linker is a compatible chelator selected from the group consisting of amine-containing derivatives of diethylenetraiminepentaacetic acid, ethylenediaminetetraacetic acid, dimercaptosuccinic acid, 2,3-dimercaptopropanesulfonic acid, metallothioein and cryptates.

Claim 23

The method according to claim 7 or 12, in which the linker is selected from the group consisting of p-aminoanaline-diethylenetriaminepentaacetic acid, hydrazidediethylenetriaminepentaacetic acid, phenylhydrazidediethylenetriaminepentaacetic acid, hydroxylaminediethylenetriaminepentaacetic acid, semicarbazidediethylenetriaminepentaacetic acid, thiosemicarbazidediethylenetriaminepentaacetic acid, polyethyleneiminediethylenetriaminepentaacetic acid, p-phenylenediaminediethylenetriaminepentaacetic acid, diethylenetriaminepentaacetic acid mono[(4-aminophenyl)methyl]amide, α-N-diethylenetriaminepentaacetic acid-L-lysine, glycyl-tyrosyl-lysine-diethylenetriaminepentaacetic acid and L-lysine benzyl ester -diethylenetriaminepentaacetic acid.

Claim 24

An antibody fragment-compound conjugate, comprising: a soluble F(ab') 2 -compound conjugate prepared by a method which comprises: reacting a soluble antibody-compound conjugate, comprising an antibody attached to a compound by a covalent bond to an oxidized carbohydrate of the antibody, located outside the antigen binding region of the antibody, with an activated thiol protease enzyme to from F(ab') 2 -compound conjugate, in which the antibody F(ab') 2 -compound conjugate is characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the F(ab') 2 -compound conjugate is suitable for in vivo administration.

Claim 25

An antibody fragment-compound conjugate, comprising: a soluble F(ab') 2 -compound conjugate prepared by a method which comprises: reacting a soluble antibody-compound conjugate, comprising an antibody attached to a compound by a covalent bond to an oxidized carbohydrate of the antibody, located outside the antigen binding region of the antibody, with an activated thiol protease enzyme to from F(ab') 2 -compound conjugate, in which the antibody F(ab') 2 -compound conjugate is characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the F(ab') 2 -compound conjugate is suitable for in vivo administration.

Claim 26

An antibody fragment-compound conjugate, comprising: a soluble F(ab') 2 -compound conjugate prepared by a method which comprises: (a) reacting an antibody-linker intermediate which comprises a linker attached via a covalent bond to an oxidized carbohydrate moiety of an antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody and in which the antibody-linker intermediate is characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the antibody-linker intermediate is suitable for in vivo administration, with an activated thiol protease enzyme to form a soluble F(ab') 2 linker intermediate; and (b) attaching the linker portion of the F(ab') 2 -linker intermediate either by a covalent or coordinate bond to a compound to form a F(ab') 2 -linker compound conjugate being characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the F(ab') 2 -linker -compound conjugate is suitable for in vivo administration.

Claim 27

An antibody fragment-compound conjugate, comprising: a soluble F(ab') 2 -compound conjugate prepared by a method which comprises: (a) reacting an antibody-linker intermediate which comprises a linker attached via a covalent bond to an oxidized carbohydrate moiety of an antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody and in which the antibody-linker intermediate is characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the antibody-linker intermediate is suitable for in vivo administration, with an activated thiol protease enzyme to form a soluble F(ab') 2 linker intermediate; and (b) attaching the linker portion of the F(ab') 2 -linker intermediate either by a covalent or coordinate bond to a compound to form a F(ab') 2 -linker compound conjugate being characterized by (i) substantially the same immunospecificity as the unconjugated antibody and (ii) aqueous solubility such that the F(ab') 2 -linker -compound conjugate is suitable for in vivo administration.

Claim 28

An antibody fragment-compound conjugate, comprising: a soluble F(ab') 2 -compound conjugate prepared by a method which comprises: reacting a soluble antibody-linker-compound conjugate, which comprises a linker-compound moiety attached via a covalent bond to an oxidized carbohydrate moiety of an antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody and in which the antibody-linker-compound conjugate is characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration, with an activated thiol protease to form a soluble F(ab') 2 -linker-compound, being characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration.

Claim 29

An antibody fragment-compound conjugate, comprising: a soluble F(ab') 2 -compound conjugate prepared by a method which comprises: reacting a soluble antibody-linker-compound conjugate, which comprises a linker-compound moiety attached via a covalent bond to an oxidized carbohydrate moiety of an antibody, in which the carbohydrate moiety is located outside the antigen binding region of the antibody and in which the antibody-linker-compound conjugate is characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration, with an activated thiol protease to form a soluble F(ab') 2 -linker-compound, being characterized by (a) substantially the same immunospecificity as the unconjugated antibody and (b) aqueous solubility such that the antibody-linker-compound conjugate is suitable for in vivo administration.

Claim 30

A method for in vivo imaging of a specific tissue, comprising: (a) administering to an animal or a human an effective amount of an aqueous soluble antibody F(ab') 2 -compound conjugate according to claim 21, 22 or 23 in which the F(ab') 2 -compound conjugate is immunoreactive with and immunospecific for an antigenic determinant of the specific tissue and non-immunospecific for non-specific tissue and in which the antigenic determinant is not found in substantial amounts in non-specific tissue; and (b) detecting the F(ab') 2 -compound conjugate localized at the specific tissue.